239 related articles for article (PubMed ID: 19372220)
1. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy.
Kuhn C; Frank D; Will R; Jaschinski C; Frauen R; Katus HA; Frey N
J Biol Chem; 2009 Jun; 284(25):17320-17327. PubMed ID: 19372220
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
3. Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling.
Hille S; Dierck F; Kühl C; Sosna J; Adam-Klages S; Adam D; Lüllmann-Rauch R; Frey N; Kuhn C
Cardiovasc Res; 2016 Jun; 110(3):381-94. PubMed ID: 27056896
[TBL] [Abstract][Full Text] [Related]
4. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
5. Hyperhomocysteinemia-induced Dyrk1a downregulation results in cardiomyocyte hypertrophy in rats.
Raaf L; Noll C; Cherifi M; Benazzoug Y; Delabar JM; Janel N
Int J Cardiol; 2010 Nov; 145(2):306-307. PubMed ID: 19906449
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between calcineurin/NFAT and Jak/STAT signalling induces cardioprotective alphaB-crystallin gene expression in response to hypertrophic stimuli.
Manukyan I; Galatioto J; Mascareno E; Bhaduri S; Siddiqui MA
J Cell Mol Med; 2010 Jun; 14(6B):1707-16. PubMed ID: 19538478
[TBL] [Abstract][Full Text] [Related]
7. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
[TBL] [Abstract][Full Text] [Related]
8. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro.
Pu WT; Ma Q; Izumo S
Circ Res; 2003 Apr; 92(7):725-31. PubMed ID: 12663489
[TBL] [Abstract][Full Text] [Related]
9. COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.
Li H; Gao S; Ye J; Feng X; Cai Y; Liu Z; Lu J; Li Q; Huang X; Chen S; Liu P
Mol Cell Endocrinol; 2014 Feb; 382(2):998-1006. PubMed ID: 24291639
[TBL] [Abstract][Full Text] [Related]
10. Aspirin Attenuates Angiotensin II-induced Cardiomyocyte Hypertrophy by Inhibiting the Ca(2+)/Calcineurin-NFAT Signaling Pathway.
Yin Z; Wang X; Zhang L; Zhou H; Wei L; Dong X
Cardiovasc Ther; 2016 Feb; 34(1):21-9. PubMed ID: 26506219
[TBL] [Abstract][Full Text] [Related]
11. NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect.
Stefos GC; Soppa U; Dierssen M; Becker W
PLoS One; 2013; 8(6):e67470. PubMed ID: 23825664
[TBL] [Abstract][Full Text] [Related]
12. Activation of HuR downstream of p38 MAPK promotes cardiomyocyte hypertrophy.
Slone S; Anthony SR; Wu X; Benoit JB; Aube J; Xu L; Tranter M
Cell Signal; 2016 Nov; 28(11):1735-41. PubMed ID: 27521603
[TBL] [Abstract][Full Text] [Related]
13. Leptin-induced cardiomyocyte hypertrophy reveals both calcium-dependent and calcium-independent/RhoA-dependent calcineurin activation and NFAT nuclear translocation.
Rajapurohitam V; Izaddoustdar F; Martinez-Abundis E; Karmazyn M
Cell Signal; 2012 Dec; 24(12):2283-90. PubMed ID: 22917533
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
Fiedler B; Lohmann SM; Smolenski A; Linnemuller S; Pieske B; Schroder F; Molkentin JD; Drexler H; Wollert KC
Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11363-8. PubMed ID: 12177418
[TBL] [Abstract][Full Text] [Related]
15. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
16. BMP type I receptor ALK2 is required for angiotensin II-induced cardiac hypertrophy.
Shahid M; Spagnolli E; Ernande L; Thoonen R; Kolodziej SA; Leyton PA; Cheng J; Tainsh RE; Mayeur C; Rhee DK; Wu MX; Scherrer-Crosbie M; Buys ES; Zapol WM; Bloch KD; Bloch DB
Am J Physiol Heart Circ Physiol; 2016 Apr; 310(8):H984-94. PubMed ID: 26873969
[TBL] [Abstract][Full Text] [Related]
17. DY-9760e inhibits endothelin-1-induced cardiomyocyte hypertrophy through inhibition of CaMKII and ERK activities.
Lu YM; Shioda N; Han F; Kamata A; Shirasaki Y; Qin ZH; Fukunaga K
Cardiovasc Ther; 2009; 27(1):17-27. PubMed ID: 19207476
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.
da Costa Martins PA; Salic K; Gladka MM; Armand AS; Leptidis S; el Azzouzi H; Hansen A; Coenen-de Roo CJ; Bierhuizen MF; van der Nagel R; van Kuik J; de Weger R; de Bruin A; Condorelli G; Arbones ML; Eschenhagen T; De Windt LJ
Nat Cell Biol; 2010 Dec; 12(12):1220-7. PubMed ID: 21102440
[TBL] [Abstract][Full Text] [Related]
19. Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway.
Bao Y; Li R; Jiang J; Cai B; Gao J; Le K; Zhang F; Chen S; Liu P
Mol Cell Biochem; 2008 Oct; 317(1-2):189-96. PubMed ID: 18600431
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated overexpression of diacylglycerol kinase-zeta inhibits endothelin-1-induced cardiomyocyte hypertrophy.
Takahashi H; Takeishi Y; Seidler T; Arimoto T; Akiyama H; Hozumi Y; Koyama Y; Shishido T; Tsunoda Y; Niizeki T; Nozaki N; Abe J; Hasenfuss G; Goto K; Kubota I
Circulation; 2005 Mar; 111(12):1510-6. PubMed ID: 15781737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
